UBS Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.1M | Sell |
45,100
-300
| -0.7% | -$140K | ﹤0.01% | 2577 |
|
|
2025
Q4 | $20.6M | Buy |
45,400
+6,300
| +16% | +$2.72M | ﹤0.01% | 2568 |
|
|
2025
Q3 | $15.3M | Buy |
39,100
+8,100
| +26% | +$3.39M | ﹤0.01% | 2860 |
|
|
2025
Q2 | $13.8M | Sell |
31,000
-24,500
| -44% | -$11.3M | ﹤0.01% | 2771 |
|
|
2025
Q1 | $26.9M | Sell |
55,500
-35,100
| -39% | -$16.4M | ﹤0.01% | 2060 |
|
|
2024
Q4 | $36.5M | Buy |
90,600
+24,700
| +37% | +$11.4M | 0.01% | 1745 |
|
|
2024
Q3 | $30.6M | Buy |
65,900
+1,600
| +2% | +$769K | 0.01% | 1502 |
|
|
2024
Q2 | $30.1M | Buy |
64,300
+1,600
| +3% | +$694K | 0.01% | 1375 |
|
|
2024
Q1 | $26.2M | Sell |
62,700
-3,500
| -5% | -$1.48M | 0.01% | 1480 |
|
|
2023
Q4 | $26.9M | Sell |
66,200
-260
| -0.4% | -$96K | 0.01% | 1376 |
|
|
2023
Q3 | $23.1M | Buy |
66,460
+25,460
| +62% | +$8.9M | 0.01% | 1379 |
|
|
2023
Q2 | $14.4M | Buy |
41,000
+13,500
| +49% | +$4.55M | ﹤0.01% | 1702 |
|
|
2023
Q1 | $8.66M | Buy |
27,500
+24,800
| +919% | +$7.44M | ﹤0.01% | 1997 |
|
|
2022
Q4 | $780K | Buy |
+2,700
| New | +$823K | ﹤0.01% | 4300 |
|
|
2022
Q2 | – | Sell |
-32,048
| Closed | -$8.36M | – | 10999 |
|
|
2022
Q1 | $8.36M | Buy |
32,048
+2,248
| +8% | +$534K | ﹤0.01% | 2076 |
|
|
2021
Q4 | $6.54M | Sell |
29,800
-2,741
| -8% | -$533K | ﹤0.01% | 2548 |
|
|
2021
Q3 | $5.9M | Hold |
32,541
| – | – | ﹤0.01% | 2499 |
|
|
2021
Q2 | $6.56M | Buy |
32,541
+14,900
| +84% | +$3.12M | ﹤0.01% | 2415 |
|
|
2021
Q1 | $3.79M | Buy |
+17,641
| New | +$3.87M | ﹤0.01% | 2904 |
|
|
2018
Q4 | – | Sell |
-48,565
| Closed | -$9.36M | – | 8325 |
|
|
2018
Q3 | $9.36M | Buy |
48,565
+46,065
| +1,843% | +$8.2M | ﹤0.01% | 1832 |
|
|
2018
Q2 | $425K | Buy |
+2,500
| New | +$388K | ﹤0.01% | 4445 |
|
|
2018
Q1 | – | Sell |
-12,700
| Closed | -$1.9M | – | 8195 |
|
|
2017
Q4 | $1.9M | Buy |
+12,700
| New | +$1.88M | ﹤0.01% | 3247 |
|
|
2016
Q1 | – | Sell |
-900
| Closed | -$113K | – | 8224 |
|
|
2015
Q4 | $113K | Sell |
900
-200
| -18% | -$24.1K | ﹤0.01% | 5121 |
|
|
2015
Q3 | $114K | Sell |
1,100
-300
| -21% | -$38.5K | ﹤0.01% | 5119 |
|
|
2015
Q2 | $173K | Buy |
1,400
+100
| +8% | +$12.6K | ﹤0.01% | 4994 |
|
|
2015
Q1 | $153K | Sell |
1,300
-128,000
| -99% | -$15.3M | ﹤0.01% | 5091 |
|
|
2014
Q4 | $15.4M | Buy |
+129,300
| New | +$14.6M | 0.01% | 1178 |
|
Other funds holding VRTX
VCM
VPM
UBS Group's VRTX Position: Q1 2026 in Review
UBS Group increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $34.8M and bringing the position to 630,618 shares worth $282M. The position accounts for 0.04% of the portfolio, ranked #455.
UBS Group first reported a position in VRTX in Q4 2014 and has held it in 46 quarters since. The position peaked at $360M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- UBS Group held 630,618 shares of Vertex Pharmaceuticals worth $282M as of Q1 2026.
- UBS Group bought 74,636 Vertex Pharmaceuticals shares in Q1 2026, an estimated $34.8M.
- Vertex Pharmaceuticals made up 0.04% of UBS Group's portfolio in Q1 2026, its #455 holding.
- UBS Group first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Vertex Pharmaceuticals position peaked at $360M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.